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Fagerstrom scoreAbstract Background: ‘‘Smoking is the main avoidable cause of death around the world”. It’s
prevalence is about one billion smokers in the global adult population. ‘‘The most cost effective
and well-documented methods for smoking cessation are professional advice combined with the
nicotine replacement therapy”. So the main aim of hospital staff must be to give advices about
smoking cessation and the ways to it. The aim of this work was to study the pharmacotherapy role
in smoking cessation giving an insight into the frequency of smoking among Zagazig University
Hospitals’ staff in 2013.
Subjects and methods: This epidemiological, observational and prospective study was carried out
at Zagazig University Hospitals from the period January 2013 to December 2013.
Subjects: 150 of those current smokers agreed to answer the study questionnaire and share in
this study. The included subjects were 144 males and 6 females with a mean age of 39.48
± 11.95 years.
Methods: The studied subjects were subjected to the following: (1) personal history including:
smoking history and family history, (2) routine investigations and (3) plain X-ray. The studied sub-
jects (150) were divided into 2 groups according to their agreement for taking pharmacotherapy:
group I: included 111 subjects treated by behavioral therapy alone for 3 months. Group II: included
39 subjects treated by behavioral therapy plus pharmacotherapy (Bupropion SR tablet) for
3 months.
Results: A statistically highly signiﬁcant percentage of subjects who did previous trial of quitting
was found in group II than that in group I. Also, there was a statistically highly signiﬁcant percent-
age of subjects who are less nicotine dependent in group II than that in group I, but the reverse was
present in highly nicotine dependent subjects according to Fagerstrom score. The ﬁnal outcome of
quitting trial with a successful cessation rate was 48%, while the failed cessation rate was 52% and
there was a statistically signiﬁcant higher successful rate in group II (69.3%) than that in group I
(40.5%). As regards occupation, the physicians had statistically highly signiﬁcant higher levels of
586 A. Mohamed et al.successful rate than para-medicals who had high levels of failed cessation rate. A statistically highly
signiﬁcant increase in the percentage of other smoker family member was found in failed cessation
group than that in successful cessation one. Regarding Fagerstrom score, there were statistically sig-
niﬁcant increases in percentage of subjects who were less nicotine dependent in successful cessation
group than that in failed cessation one and also in percentage of subjects who were highly nicotine
dependent in failed cessation group than that in successful one.
Conclusion: (1) Programs promoting smoking cessation including behavioral therapy in addition
to the complementary role of pharmacotherapy (Bubropion SR) enhanced the chance of success in
smoking cessation. (2) This pilot study (regarding the number of the studied individuals) pointed to
the smoking dilemma in a locality where smoking behavior should be brought to a minimum espe-
cially among physicians.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
‘‘Smoking is the main avoidable cause of death around the
world”. Its prevalence is about one billion smokers in the glo-
bal adult population [1]. Hospitals have an important role in
the struggle to reduce the use of tobacco and its dangerous
health effects. Tobacco smoking in medical staff affects occu-
pational health. ‘‘Apart from its signiﬁcant impact on patient’s
health, tobacco usage also represents an important occupa-
tional health issue in the medical profession” [2]. Although
most smokers try to quit smoking, only 2–4% succeeds in quit-
ting yearly. Hospitals play an important role in smoking cessa-
tion. ‘‘The most cost effective and well-documented methods
for smoking cessation are professional advice combined with
the nicotine replacement therapy”. So the main aim of the hos-
pital staff must be to give advices about smoking cessation and
the ways to it [3]. The aim of this work was to study the phar-
macotherapy role in smoking cessation giving an insight into
frequency of smoking among Zagazig University Hospitals’
staff in 2013.
Subjects and methods
This epidemiological, observational and prospective study was
carried out at Zagazig University Hospitals from the period
January 2013 to December 2013.
Subjects
Four thousand and ﬁve hundred subjects are working at
Zagazig University Hospitals including; 800 physicians, 1300
nurses, 2000 workers and 400 paramedicals. By asking about
their smoking habit, there were 1200 subjects having smoking
history; 800 of them were current smokers. Only 150 of those
current smokers agreed to answer the study questionnaire and
share in this study.
The included subjects in this study were 144 males and 6
females with a mean age of 39.48 ± 11.95 years.
Methods
The studied subjects were subjected to the following:Personal history
1. Age, sex, occupation, education and medical history.
2. Smoking history of subject’s smoking condition at the start
of smoking cessation as regards:
(a) Cigarettes smoking:– Age of onset of smoking.
– Number of cigarettes smoked per day.
– Duration of smoking.
– Fagerstrom test questionnaire was used to deter-
mine the degree of nicotine dependence [4].
Cigarette smokers were categorized into 3-groups
according to pack-year classiﬁcation into (mild,
moderate and heavy) [5].
– Mild > 20.
– Moderate 20–49.
– Heavy > 49.Fagerstrom test for nicotine dependence [4]:Question Answer Score1. How soon after you wake up do you Within 5 min 3smoke your ﬁrst cigarette? 6–30 min 231–60 min 1After 60 min 02. Do you ﬁnd it diﬃcult to refrain from
smoking in places where it is forbidden?Yes
No1
03. Which cigarette would you hate to
give up most?The ﬁrst one in
the morning1All others 04. How many cigarettes per day do 10 or less 0you smoke? 11–20 121–30 231 or more 35. Do you smoke more frequently
during the ﬁrst hours after waking than
during the rest of the day?Yes
No1
06. Do you smoke if you are so ill that Yes 1you are in bed most of the date No 0
Role of pharmacotherapy in smoking cessation 587Calculating the points acquired from each question determines
whether the subject is dependent on nicotine or not.
Scoring
– 7 to 10 points = highly dependent.
– 4 to 6 points = moderately dependent.
– Less than 4 points = less dependent.
Higher scores indicate that withdrawal symptoms from
quitting of tobacco are more likely and it is likely to be
stronger.
(b) Shisha smoking:– Number of Shisha sessions per day.
– Shisha session duration (in minutes).
History of previous trials of smoking quitting:
– Number of trials.
– Duration of quitting.
– Cause of quitting trials.
– Cause of quitting failure.3. Family history: of illness of medical importance and if there
was any other home smoker member.
4. Routine investigations: complete blood count, kidney and
liver functions.
5. Plain X-ray (posteroanterior and lateral views).
Then the studied subjects (150) were divided into 2 groups
according to their agreement for taking pharmacotherapy:
Group I: included 111 subjects treated by behavioral ther-
apy alone for 3 months.
Group II: included 39 subjects treated by behavioral therapy
plus pharmacotherapy (Bupropion SR tablet) for 3 months.
Behavioral therapy: [Physician’s advice was based on the
National Network of Tobacco Cessation Quit Lines (2011)].
How to quit smoking?
Smoking is dangerous to your health. Quitting will reduce
your risk of dying from heart diseases, blood vessel diseases,
lung problems, cancer and stroke. Before you try to stop
smoking, commit to stop. Smoking is a learned behavior that
you must unlearn. It is not easy to stop. But it can be done if
you are serious about quitting. Stopping will help you to live a
healthier and longer life.
Getting ready to quit
Follow these steps to get ready to quit:
– Cut down the number of cigarettes you smoke each day.
– Smoke only half a cigarette each time.
– Smoke only during the even hours of the day.
– Clean out ashtrays and start putting them away one by one.
Clean the drapes, the car, your ofﬁce or anything else that
smells of tobacco smoke. Get a friend or spouse to quit with
you.– Start exercising before you quit.
– Switch to a brand of cigarettes you do not like as much.
– Throw away spare lighters.
– Smoke alone if you like to smoke with people.
– Write down a list of the top 5 reasons you want to quit.
Read this list daily.
– Pick a date to quit and slowly reduce your smoking until
your quit date.
The day you quit
– Throw away your cigarettes, lighters and hind remaining
ashtrays.
– Ask for help from family and friends.
– Drink 8 glasses of water each day. This helps ﬂush out the
nicotine in your body.
– Keep celery, sugarless gum, hard candy, straws or tooth-
picks handy to help meet the urge of something in your
mouth.
– Try deep breathing exercises and listen to relaxation tapes.
– Exercise.
– Eat regular meals.
– Start a money jar with the money you save by not buying
cigarettes.
– Reward yourself at the end of the day for not smoking.
Over the next days and weeks you may be coping with with-
drawal symptoms and cravings. Exercise and relaxation can
help with withdrawal symptoms of anger or irritability. There
will be times when you really want to smoke, wait. The urge
will pass in a few minutes. Take slow, deep breaths until you
relax and forget about the urge to smoke. Drink water slowly
and hold it in your mouth for a little while. Take your mind off
smoking by thinking about something else or focus on the
things you are doing. It is hard to quit smoking. Most people
try several times before they succeed. If you do smoke, you do
not give up on yourself, remind yourself of how many hours,
days or weeks you have already gotten through. Identify what
caused you to smoke. Add it to your list of things to avoid or
practice how you will deal with it next time. Remind yourself
why you quit smoking. Practice what to do when you feel
the urge to smoke, reward yourself for your well power and
courage. Talk to your doctor or nurse if you have any ques-
tions or concerns.Pharmacotherapy
Treatment by Bupropion SR 150 mg tablet (Wellbutrin SR
150 mg tab.) should be started at least one week before cessa-
tion date with follow up visits; 1 week and 1 month after the
quitting date. Usually we start, by one tablet for one week then
twice daily for 3 months [6].Exclusion criteria of Bupropion SR usage
Bupropion is contraindicated in those with a seizure disorder,
those with anorexia or bulimia, or those who have used a
monoamine oxidase inhibitor (e.g. selegiline [Eldepryl], tranyl-
cypromine [Parnate], phenelzine [Nardil] within the previous
14 days. Health care providers interested in prescribing
Table 1 Demographic data of all studied patients.
Parameter No. (n= 150) %
Sex Male 144 96
Female 6 4
Age M± SD 39.48 ± 11.95
Type of smoking Cigarette smoking 126 84
Shisha smoking 7 4.7
Combined 17 11.3
Occupation Para-medicals 78 52
Physicians 66 44
Workers 6 4
Education Literate 144 96
Illiterate 6 4
Previous trial of quitting Yes 40 26.7
No 110 73.3
Cause of trial Health concern 36 90
Economic cause 3 7.5
Religious causes 1 2.5
Cause of relapse Being around other tobacco users 18 45
Withdrawal symptoms 16 40
Habit 6 15
Other smoker family member Yes 90 60
No 60 40
Frequency of smoking among hospitals’ staﬀ Having smoking history 1200 26.67
Current smokers 800 17.78
588 A. Mohamed et al.Bupropion should thoroughly review the manufacturer’s
product information before deciding to initiate therapy [7].
Statistical analysis
Statistical analysis was performed with the SPSS statistical
software package (SPSS Inc., Chicago, IL).
Data presented by mean ± SD for quantitative continuous
data and comparison between several group means were calcu-
lated by one way analysis for variance (F test) and post-hoc
analysis (LSD) was done.
Qualitative data were presented by number and percentage
and association was tested by Chi-square test.
Results
Table 1 showed the demographic data of all studied patients.
Regarding type of smoking, the majority of subjects were
cigarette smokers (84%), while Shisha smokers represented
only 4.7%. The commonest cause of previous quitting trial
was health concern (90%). As regards the cause of relapse,
45% of the studied subjects relapsed to smoking because of
being around other tobacco users, 40% because of withdrawal
symptoms and 15% as a habit. Regarding frequency of smok-
ing among hospitals’ staff, 26.67% of subjects have smoking
history and 17.78% of subjects were current smokers.
Table 2 showed statistically non-signiﬁcant differences
between the two groups of therapy regarding age, sex, occupa-
tion and education. But statistically highly signiﬁcant percent-
age of subjects who did previous trial of quitting was found in
group II than that in group I (P= 0.001). Also, there was sta-
tistically highly signiﬁcant percentage of subjects who are lessnicotine dependent in group II than that in group I, but the
reverse was present in highly nicotine dependent subjects
according to Fagerstrom score (P< 0.001).
Table 3 showed the ﬁnal outcome of quitting trial with a
successful cessation rate was 48%, while the failed cessation
rate was 52%. Also, there was a statistically signiﬁcant higher
successful rate in group II (69.3%) than that in group I
(40.5%) (P= 0.002).
Table 4 showed non-signiﬁcant differences between success-
ful and failed cessation groups regarding age and sex. But as
regards occupation, the physicians had statistically highly sig-
niﬁcant higher levels of successful rate than para-medicals who
had high levels of failed cessation rate (P< 0.001). There were
statistically non-signiﬁcant differences between both groups as
regards education and the previous trial of quitting (P> 0.05).
A statistically highly signiﬁcant increase in the percentage of
other smoker family member was found in failed cessation
group than that in successful cessation one (P< 0.001).
Regarding Fagerstrom score, there were statistically signiﬁcant
increases in percentage of subjects who were less nicotine
dependent in successful cessation group than that in failed ces-
sation one (P= 0.004) and also in the percentage of subjects
who were highly nicotine dependent in failed cessation group
than that in successful one (P= 0.026).
Discussion
Tobacco is the most common substance used in smoking prac-
tice which is burned and the smoke inhaled or tasted. It is
administered by this route for releasing the active substances
as nicotine and absorbed through the lungs. ‘‘Tobacco is the
single most preventable cause of death in the world today. It
Table 2 Comparison between the two groups of therapy as regards age, sex, occupation, education, previous trial of quitting, other
smoker family member and Fagerstrom score.
Parameter Group I (n= 111) Group II (n= 39) P-value
Age (M± SD) 37.81 ± 8.79 41.15 ± 15.1 0.082
Sex Male 105 (94.6%) 39 (100%) 0.339
Female 6 (5.4%) 0 (0.0%)
Occupation, No. (%) Paramedicals 57 (51.4%) 21 (53.8%) 0.788
Physicians 48 (43.2%) 18 (46.2%) 0.752
Workers 6 (5.4%) 0 (0.0%) 0.138
Education Literate 105 (94.6%) 39 (100%) 0.339
Illiterate 6 (5.4%) 0 (0.0%)
Other smoker family member Yes 65 (58.6%) 26 (66.7%) 0.372
No 46 (41.4%) 13 (33.3%)
Previous trial of quitting Yes 22 (19.8%) 18 (46.2%) 0.001
No 89 (80.2%) 21 (53.8%)
Fagerstrom score Less dependent 16 (14.4%) 17 (43.6%) <0.001
Moderately dependent 34 (30.6%) 14 (36%) 0.544
Highly dependent 61 (55%) 8 (20.4%) <0.001
Table 3 Final outcome of quitting trial in all studied subjects and comparison between the two groups of therapy as regards it.
Parameter Total (n= 150) Group I (n= 111) Group II (n= 39) P-value
No. % No. % No. %
Final outcome Successful cessation 72 48 45 40.5 27 69.3 0.002
Failed cessation 78 52 66 59.5 12 30.7
Role of pharmacotherapy in smoking cessation 589kills more than ﬁve million people/year”. It is a must that
action be taken as tobacco could kill one billion people this
century [8].
Some religions disapprove smoking as Islam which pro-
hibits it as smoking harms the body. Despite that, smoking
is very popular in Egypt as 28% of Egyptians are smokers,
‘‘about 19 million smokers in the year 2000” [9]. ‘‘Tobacco
dependence is a chronic condition” and need many interven-
tions but many treatments which are effective and many
resources exist. Smokers try and quit smoking and now there
are more ex-smokers than current ones [10]. The development
and introduction of therapy by drugs offered a great help for
smokers who are trying to stop smoking especially for more
nicotine-dependent smokers. But no other pharmacotherapy
is a surrogate for motivation [11]. So the aim of this work is
to study the pharmacotherapy role in smoking cessation giving
an insight into the frequency of smoking among Zagazig
University Hospitals’ staff in 2013.
This study included 150 subjects with a mean age of 39.48
± 11.94 years, ranging from 28 to 56 years. They were 144
males and 6 females (Table 1). This result is in consistence with
the result of Kumar et al. [12] who studied 459 subjects, the
mean age of them was 39.2 ± 13.5 years with 97.4% males
and 2.4% females. This means that the most common age
who sought help for quitting smoking is the middle age. Only
4% of female smokers sought help for quitting smoking in
spite of a higher percentage of smokers ones in urban areas
[13]. Also, Santi et al. [14] found ‘‘smoking is generally ﬁve
times more prevalent among males than females with about
47.5% of men and 10.3% of women are current smokers”.Despite tobacco use prevalence has decreased among men in
developed countries, it is still increasing among females and
young people [10]. Females in these days, smoke equal or even
more than males and this may be explained by psychological
problems or the improvement of economic state. This agreed
with Santi et al. [14] who found that teenage females have a
high incidence of cigarette consumption during the past dec-
ade. This may be explained by the increasing availability of
low-nicotine cigarettes. And nowadays male and female smok-
ing behavior has become similar.
In this study, there were statistically non-signiﬁcant rela-
tions between age, sex and smoking. This may be due to envi-
ronmental and cultural differences. Furthermore, the current
study recorded that the subjects who sought help for the quit-
ting of smoking were mostly literate (96%) with variable levels
of education (Table 1). This result is in agreement with Kumar
et al. [12] who stated that ‘‘the smokers who attended to the
clinic were mostly literate”. Also, this study agreed with Tsoh
et al. [15] who found that ‘‘higher education was associated
with intention to quit”. The literate can understand the harm-
ful effects of smoking and decide seriously to stop smoking
with ‘‘well stratiﬁcation before dealing with them was easier
than illiterates”.
In the current study, the majority of subjects were cigarette
smokers (84%), while Shisha smokers represent only 4.7% and
smokers of both cigarettes and Shisha were 11.3% (Table 1).
This low percentage of Shisha smokers may be explained by
misunderstanding of content of water pipe smoke may lead
to underestimate the health hazards. But nowadays, water pipe
tobacco smoking is increasing worldwide. In fact, many of the
Table 4 Final outcome of quitting trial as regards age, sex, occupation, education, other smoker family member, the previous trial of
quitting and the Fagerstrom score.
Parameter Final outcome P-value
Successful cessation Failed cessation
No. % No. %
Age (M± SD) 41.2 ± 14.4 40.7 ± 13.3 0.821
Sex, No. (%) Male 70 97.2 74 94.9 0.682
Female 2 2.8 4 5.1
Occupation Paramedicals 18 25 60 77 0.001>
<0.001
0.453
Physicians 52 72 14 18
Workers 2 3 4 5
Education Literate 70 97.2 74 94.9 0.211
Illiterate 2 2.8 4 5.1
Previous trial of quitting Yes 22 30.6 18 23 0.301
No 50 69.4 60 77
Other smoker family member Yes 27 37.5 63 81 0.001>
No 45 62.5 15 19
Fagerstrom score Less dependent 28 39 14 17.7 0.004
Moderately dependent 20 27.7 24 30.8 0.688
Highly dependent 24 33.3 40 51.5 0.026
590 A. Mohamed et al.same chemicals in cigarette smoke present in water-pipe
tobacco and the smokers are exposed to ‘‘dependence produc-
ing drug nicotine and other smoke toxicants” [16]. Manufac-
turers of tobacco became targeting Egyptian men as
‘‘Eastern company that conﬁrming the relationship between
mild, fruit-ﬂavored water pipe tobacco and gendered smoking
preference”. The most common and most preferred ﬂavor is
apple because it is ‘‘light and ﬂavored with a wonderful fruity
aroma” [17]. Regarding the motivations of the previous trial of
quitting, the commonest cause of trial was health concern
(90%). And most of the subjects relapsed to smoking because
of; being around other tobacco users (45%), withdrawal symp-
toms (40%), and as a habit (15%) (Table 1). While, Guirguis
et al. [18] who studied 150 subjects and found that ‘‘the pri-
mary motivation for quitting was to improve general health
(42.3%) and the barriers to quit were breaking the habit, stress
and weight gain, also they found the most common causes of
relapse were falling back into the habit (36%), stressful situa-
tions (27%) and being around other smokers (25%). In this
study, there was a statistically highly signiﬁcant difference
regarding a previous trial to quit smoking (Table 2) between
the two groups (46.2% in group II and 19.8% in group I) most
probably because all (100%) of group II were males and edu-
cated and the number of physicians was higher than group I.
Regarding the presence of other smoker family member, there
was a statistically non-signiﬁcant difference between both
groups(I and II) (Table 2). The majority of group II (66.7%)
had a smoker family member who probably led them to try
to quit smoking. The ﬁnal outcome of the smoking cessation
was successful in 48% and 52% failed (Table 3) with group
II individuals having a successful cessation rate greater than
group I (69.3% vs 40.5%) with a statistically highly signiﬁcant
difference (Table 3). This result pointed to the importance of
combination therapy. Neither age nor sex of subjects had an
effect on cessation outcome (Table 4). On the other hand,
physicians had a higher success rate (72%) (Table 4). In the
current study, 40 (26.7%) subjects had previous trial of quit-ting with statistically non-signiﬁcant difference between suc-
cessful cessation group and failed one (Table 4). This result
agreed with Chung and Jennifer [19] result which showed no
correlation was present between successful cessation and
repeated trials of quitting of smoking. In discordance with
our result, Hymowitz et al. [20] reported that successful cessa-
tion is associated with many trials of quitting of smoking. In
this study, the majority of subjects who failed to stop smoking
had other family members who are smokers and vice versa
(Table 4) and this means that surroundings have very impor-
tant psychological support to stop smoking and from other
points, just the presence of nicotine smell in the smoker envi-
ronment cause easy relapse. This result is in agreement with
Cook and Strachan [21] who found that ‘‘children who smoked
were likely to have parents who smoked and both older and
younger siblings were smoked, thus creating entire smoking
family”. As regards Fagerstrom score, there was a statistically
highly signiﬁcant increase in the percentage of subjects who are
less nicotine-dependent in successful cessation group than that
in failed cessation one and a statistically signiﬁcant increase in
the percentage of subjects who are highly nicotine-dependent
in failed cessation group than that of successful cessation
one (Table 4). This result means that those of less nicotine-
dependent have the motivation to stop smoking more than
those of high nicotine-dependent. ‘‘Motivation to quit and stay
quitting is characterized by ambivalence and conﬂict”. Quit-
ting smoking usually leads to bad moods. So it is very impor-
tant to use competing resources to overcome returning to
smoking [22]. Our result is in accordance with that of Hymow-
itz et al. [20] who reported that heavy smokers are more likely
than light smokers to fail quitting of smoking but it disagreed
with Celia et al.[23] who showed no relation between success of
smoking stopping and number of cigarettes smoked per day.
The addictive potential of nicotine supported by withdrawal
symptoms of nicotine is accompanied by drug-seeking behav-
ior. Nowadays, many concepts ‘‘suggest that both the psy-
choactive effects of nicotine and its addiction potential
Role of pharmacotherapy in smoking cessation 591depends on its pharmacokinetics. The effect of nicotine on
CNS depends on its absolute level and the level of it at the
receptors [24].
Conclusion
1. Programs promoting smoking cessation including behav-
ioral therapy in addition to the complementary role of
pharmacotherapy (Bupropion SR) enhanced the chance
of success in smoking cessation.
2. This pilot study (regarding the number of the studied indi-
viduals) pointed to the smoking dilemma in a locality where
smoking behavior should be brought to a minimum espe-
cially among physicians.
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